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OBJECTIVES: GBS is a neuromuscular disease affecting
180 to 720 Canadians each year. Patients with GBS may
be paralyzed for months, and up to 15% of affected
patients are left with a long-term disability. Until rela-
tively recently, standard therapy for GBS was a 5-day
course of PE. As an alternative to PE, more recent 
randomized trials demonstrate that intravenous IVIG is
equally effective to PE, but has fewer side effects and is
easier to administer. Since clinicians have two options for
the treatment of GBS, a cost utility analysis was con-
ducted to determine which of these two treatments is the
most cost effective. METHODS: A decision model was
developed to simulate treatment response and disease
recurrence over a 12-month time horizon. Clinical data
were obtained from a meta analysis of randomized trials.
Six experienced nurses were interviewed to obtain Health
care resource utilization data. Utility values were
obtained through interviews with 12 GBS health care
providers using the Time Trade-Off technique. RESULTS:
Based on the resource use data collected, the mean direct
cost of a 5-day treatment of IVIG and PE was $9785
(95% CI: $9637–$9933) and $7508 ($6577–$8439)
respectively. Using cost and utility estimates from IVIG
and PE, the cost per quality adjusted life year (QALY)
gained with IVIG was $35,700. In addition all of the
health care providers interviewed preferred the use of
IVIG instead of PE for their patients. CONCLUSIONS:
For the treatment of GBS, IVIG has a more favorable side
effect proﬁle and is easier to administer than PE. These
product attributes result in an incremental cost per QALY
gained that is considered economically acceptable by
current standards.
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OBJECTIVES: To examine utilization of various narcotic
analgesics that are used in pain management of occupa-
tional injuries among West Virginia Worker’s Compensa-
tion claimants. METHODS: We reviewed all claimants
(N = 20,282) who had any narcotic analgesic prescrip-
tion reimbursement during a period between July 1, 1997
and June 30, 2002. This accounted for 8% of all injury
claimants (N = 253,841) and 53.5% of all claimants 
with any prescription reimbursements (N = 37,903). We
analyzed all narcotic analgesic claims by types of drug,
extent, and duration of use and cost of the drug. We 
also studied the trend and pattern of utilization of these
medications between ﬁscal years FY1998 and FY2002.
RESULTS: The proportion of claimants with narcotic
analgesic prescription reimbursements increased by
almost 3 times from 7.8% in FY1998 to 24.4% in
FY2002. During the same period, total costs of narcotic
analgesics increased by 18 times. Most of the narcotic
analgesics were utilized in claimants who had a diagno-
sis of multiple musculoskeletal sprains (40.8%), multiple
injuries (21.2%), severe trauma (20.6%) and back injury
(7.0%). Twenty-nine percent of cases utilized more than
one narcotic analgesic. The most frequently prescribed
narcotic analgesic was hydrocodone with acetaminophen
(40.8%), followed by propoxyphene napsylate (12.6%),
Ultram (11.8%) and Oxycontin (8.9%). Although Oxy-
contin was utilized in 8.9% of the claimants, it accounted
for 34.8% of the total narcotic analgesic expenditure in
this population. Of all the narcotic analgesics, Oxycon-
tin had the highest median cost ($453 per claimant) and
median duration of use per claimant (97 days). CON-
CLUSION: Cost and utilization of narcotic analgesics
have dramatically increased over the past ﬁve years
among WV Workers Compensation claimants. Almost
90% of narcotic analgesic utilization is concentrated in
claimants with diagnosis of musculoskeletal sprains,
severe trauma, back and multiple injuries. High utiliza-
tion and duration of use of Oxycontin needs attention due
to its highly addictive nature and cost implications.
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OBJECTIVES: The objectives of this study were to deter-
mine and compare the prevalence and direct costs of back
pain in the U.S. in 1996 and 1999. METHODS: Retro-
spective analysis was conducted of the 1996 and 1999
portions of the Medical Expenditure Panel Survey
(MEPS). The MEPS collected data from nationally repre-
sentative samples of 22,601 respondents (1996) and
24,618 respondents (1999) and from respondents’ health
care and insurance providers. Data used for this study
included medical conditions and use and payments for
medical care. Back pain patients were identiﬁed using
ICD-9-CM codes determined by an expert panel of physi-
cians and professional coders as indicative of back pain.
Direct costs were calculated using patient and third-party
payments for back pain related medical events by type of
medical care. Sample estimates were weighted and pro-
jected to the population and 95% conﬁdence limits were
calculated using the Taylor expansion method. RESULTS:
There was no signiﬁcant difference in the prevalence of
back pain between 1996 (8.74%) and 1999 (9.00%).
From 1996 to 1999, total direct costs increased from
$14,701,417,650 to $25,847,917,882. Total inpatient
stay expenditures represented the largest proportion 
of this increase in direct costs, increasing from
$4,658,655,867 (mean = $10,016; 95% CL =
$9,463–$10,579) to $12,809,062,318 (mean = $17,305;
95% CL = $4,762–$29,847). Total expenditures on home
